EULAR: Febuxostat Bests Allopurinol in Gout - MedPage Today

EULAR: Febuxostat Bests Allopurinol in Gout MedPage Today "Achievement and maintenance of goal-range serum urate did not occur in many gout patients treated with allopurinol at the most commonly used dose of 300 ... and more »

Febuxostat Appears to Outperform Allopurinol in Percentage of Gout Patients ... - DG News

Febuxostat Appears to Outperform Allopurinol in Percentage of Gout Patients ... DG News "Achievement and maintenance of goal-range serum urate did not occur in many gout patients treated with allopurinol at the most commonly used dose of 300 ... and more »

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ... - MarketWatch (press release)

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ... MarketWatch (press release) Data suggest that many patients discontinue allopurinol within the first few months of therapy, in part due to increased flares," said H. Ralph Schumacher, ... Regeneron's Gout Drug Meets Trial Goals In One Late-stage Study; Disappoints ...Stock Markets Review all 74 news articles »

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ... - AUTO-MOBI.info (press release)

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ... AUTO-MOBI.info (press release) Allopurinol reduces the production of uric acid in the body to prevent the occurrence of gout attacks with long-term use. Approximately 750000 gout patients ... and more »